FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 25-0 that 0.5 mg/day of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) was effective at reducing the clinical exacerbations of multiple sclerosis and concluded the safety data justified approval of the small molecule to treat relapsing forms of MS. Nevertheless, both the agency and the panel were concerned by safety signals